Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01724489 · ClinicalTrials.gov registry record · NA
Study of Growth Hormone and Bone in Obesity
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 77
- Enrollment target
NCT01724489 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 77 participants.
The verdict
NCT01724489, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 77 participants
- Enrollment target
Study Summary
Obesity is an important risk factor for osteoporosis and fractures. With the growing prevalence of obesity in the U.S., understanding the pathophysiology of bone loss in this population is of importance to public health. Growth hormone (GH) is a critical mediator of bone homeostasis and is markedly reduced in obesity. Our preliminary data suggest an important role for the GH/insulin-like growth factor 1 (IGF-1) system in the pathogenesis of bone loss in obesity. The development of novel imaging techniques provides an opportunity to investigate the effects of GH on skeletal structure and strength, which will provide insights into the pathogenesis of obesity related bone loss. Understanding the pathophysiology of bone loss in obesity may help identify new treatment targets for this important complication. The investigator hypothesizes that low-dose GH administration for 18 months will improve skeletal health.
Interventions
- DRUG Placebo
- DRUG Growth hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2013-08 |
| Est. Completion | 2019-04-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01724489
The ClinicalTrials.gov registry entry for NCT01724489 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01724489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01724489 about?
NCT01724489 is a clinical study titled "Study of Growth Hormone and Bone in Obesity". Obesity is an important risk factor for osteoporosis and fractures. With the growing prevalence of obesity in the U.S., understanding the pathophysiology of bone loss in this population is of importance to public health. Growth hormone (GH) is a critical mediator of bone homeostasis and is markedly ...
What is the current status of trial NCT01724489?
This trial is currently completed. It is a NA study. The enrollment target is 77 participants. The study started on 2013-08. Estimated completion is 2019-04-01.
What interventions are being tested in trial NCT01724489?
The interventions under investigation include: Placebo (DRUG), Growth hormone (DRUG).
Who is sponsoring clinical trial NCT01724489?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.